Print
Email
The cost of insulin has risen significantly, making it unaffordable for many patients with diabetes. Several factors contribute to the pricing of insulin, including research and development costs, production expenses, marketing expenses, patent protection, regulatory requirements, and the complex supply chain involved in getting insulin from manufacturers to patients. However, it is important to note that the pricing of insulin varies across different countries and healthcare systems. In some countries, such as the United States, the cost of insulin has been particularly high compared to other nations. This has led to public outcry and calls for action to address insulin affordability.
The recent Senate Health Committee hearing on making insulin more affordable shed light on the efforts being made by pharmaceutical companies and pharmacy benefit managers (PBMs) to address the skyrocketing prices of this life-saving diabetes drug. While some positive steps have been taken, there is still a need for concrete actions to ensure that every American with diabetes can access insulin at an affordable price. BioIntel360 analyses the commitments made by executives from Eli Lilly, Novo Nordisk, and Sanofi, along with the role of PBMs, the impact of government caps, and the importance of ongoing legislative efforts.
Dave Ricks, the CEO of Eli Lilly, made a notable statement at the hearing by promising not to raise pricing on the company's current insulin products.
This commitment, specifically made for Eli Lilly's insulin products, demonstrates a proactive approach in addressing the affordability issue. In fact, Ricks highlighted that they have been cutting prices. Novo Nordisk's CEO, Lars Fruergaard Jørgensen, expressed a commitment to limiting price increases to single digits, showing a willingness to control the rising costs. Sanofi's CEO, Paul Hudson, emphasized the company's responsible pricing policy and highlighted falling net prices for their insulin products.
Additionally, the three companies announced significant price reductions for their widely used insulin products, including Eli Lilly's price reduction for Lispro injection and Humalog and Humulin injections, Novo Nordisk's list price cuts for NovoLog, Levemir, and Novolin, and Sanofi's planned price reductions for Lantus and Apidra. These actions, driven by public pressure, are positive steps toward making insulin more affordable for individuals with diabetes.
Executives from significant PBMs, who bargain drug pricing with makers on behalf of health insurance companies, were also interviewed during the hearing. PBMs have come under fire for allegedly inflating prescription costs and failing to pass on all negotiated rebates and savings to customers.
Joyner emphasized CVS Health's transparency in passing on over 98% of rebates back to clients. However, concerns were raised about the portion of the dollar retained by PBMs, highlighting the need for further scrutiny and accountability.
The cost of monthly insulin for Medicare users is now capped at $35 thanks to the Inflation Reduction Act, which was signed by President Biden last year. Although this was a good move, it did not adequately safeguard diabetic people with private insurance. More than 2 million individuals with diabetes who are privately insured and take insulin nevertheless have to deal with heavy financial pressures, and over 150,000 uninsured patients are impacted.
Senators Susan Collins and Jeanne Shaheen have introduced legislation that is bipartisan in response. The proposed law would limit the cost of various types and dosage forms of insulin to $35 per month for private health insurance. These initiatives are essential for extending affordability safeguards to a greater group of people who are insulin dependent. These efforts are crucial in extending affordability protections to a larger population of insulin-dependent individuals.
While the commitments made by Eli Lilly, Novo Nordisk, and Sanofi, as well as the recent price reductions are steps in the right direction, it is vital to ensure that these promises translate into tangible outcomes. Continued vigilance and accountability from both the pharmaceutical industry and PBMs are essential to address the affordability crisis surrounding insulin. Legislative efforts, such as the proposed bipartisan legislation, play a significant role in enacting comprehensive and lasting solutions.
BioIntel360 suggests that by collaborating and pooling their efforts, stakeholders have the power to ensure that insulin, a vital medication for individuals with diabetes, is accessible and affordable for all patients. This collective approach involves various groups such as pharmaceutical companies, healthcare providers, policymakers, patient advocacy organizations, and research institutions, among others, working towards a common goal of improving insulin affordability and availability.
